Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980

被引：0
|
作者：
Shapiro, C. L.
Halabi, S.
Gibson, G.
Weckstein, D. J.
Kirshner, J.
Sikov, W. M.
Winer, E. P.
Hudis, C. A.
Isaacs, C.
Weckstein, D.
Schilsky, R. L.
Paskett, E.
机构：
[1] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[2] Duke Univ, Durham, NC USA
[3] New Hampshire Oncol Hematol PA, Hooksett, NH USA
[4] Hematol Oncol Associates Cent New York, Syracuse, NY USA
[5] Miriam Hosp, Providence, RI 02906 USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] Georgetown Univ, Washington, DC USA
[9] Univ Chicago, Chicago, IL 60637 USA
[10] New Hampshire Oncol Hematol, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
512
引用
收藏
页数：1
相关论文
共 8 条
  • [1] Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
    Shapiro, C. L.
    Halabi, S.
    Hars, V.
    Archer, L.
    Weckstein, D.
    Kirshner, J.
    Sikov, W.
    Winer, E.
    Burstein, H. J.
    Hudis, C.
    Isaacs, C.
    Schilsky, R.
    Paskett, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (05) : 683 - 689
  • [2] Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer
    Tevaarwerk, A.
    Stewart, J. A.
    Love, R.
    Binkley, N. C.
    Black, S.
    Eickhoff, J.
    Mulkerin, D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients.: The effect of adjuvant clodronate treatment
    Vehmanen, L
    Saarto, T
    Elomaa, I
    Mäkelä, P
    Välimäki, M
    Blomqvist, C
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (18) : 2373 - 2378
  • [4] Influence of zoledronic acid on bone mineral density in premenopausal women with hormone receptor positive or negative breast cancer and neoadjuvant or adjuvant chemotherapy or endocrine treatment
    Hadji, P.
    Kauka, A.
    Kalder, M.
    Bauer, T.
    Albert, U.
    Muth, M.
    Ziller, M.
    EJC SUPPLEMENTS, 2010, 8 (03): : 62 - 62
  • [5] Influence of zoledronic acid on bone mineral density in premenopausal women with hormone receptor positive or negative breast cancer and neoadjuvant or adjuvant chemotherapy or endocrine treatment
    Ziller, M.
    Hadji, P.
    Kauka, K.
    Bauer, T.
    Albert, U. S.
    Muth, M.
    Kalder, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 277
  • [6] Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial.
    Brufsky, A
    Harker, WG
    Beck, JT
    Carroll, R
    Tan-Chiu, E
    Seidler, C
    Lacerna, L
    Thomas, E
    Perez, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 12S - 12S
  • [7] Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid - new results from ABCSG-12
    Gnant, M.
    Mlineritsch, B.
    Luschin-Ebengreuth, G.
    Kainberger, F.
    Kaessmann, H.
    Piswanger-Soelkner, C.
    Seifert, M.
    Schippinger, W.
    Menzel, C.
    Dubsky, P.
    Fitzal, F.
    Steger, G.
    Greil, R.
    Marth, C.
    Kubista, E.
    Samonigg, H.
    Jakesz, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S8 - S8
  • [8] Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12
    Gnant, M.
    Mlineritsch, B.
    Schippinger, W.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Menzel, C.
    Jakesz, R.
    Kubista, E.
    Marth, C.
    Greil, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
1